
Lilly partners with Innovent to develop cancer therapies
Executive Summary
Eli Lilly & Co. penned an agreement with Innovent Biologics Inc. to develop at least three new cancer drugs in China over the next ten years.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com